Olle Ringden

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5311376/publications.pdf

Version: 2024-02-01

		5126	4035
372	37,250	86	182
papers	citations	h-index	g-index

375	375	375	22081
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. Blood Advances, 2022, 6, 339-357.	2.5	35
2	Mesenchymal Stromal Cells for Enhancing Hematopoietic Engraftment and Treatment of Graft-Versus-Host Disease, Hemorrhages and Acute Respiratory Distress Syndrome. Frontiers in Immunology, 2022, 13, 839844.	2.2	44
3	Oral mucositis after tacrolimus/sirolimus or cyclosporine/methotrexate as graftâ€versusâ€host disease prophylaxis. Oral Diseases, 2021, 27, 1217-1225.	1.5	4
4	Cytokine levels following allogeneic hematopoietic cell transplantation: a match-pair analysis of home care versus hospital care. International Journal of Hematology, 2021, 113, 712-722.	0.7	1
5	Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2021, 56, 2108-2117.	1.3	6
6	Impact of Previously Unrecognized HLA Mismatches Using Ultrahigh Resolution Typing in Unrelated Donor Hematopoietic Cell Transplantation. Journal of Clinical Oncology, 2021, 39, 2397-2409.	0.8	19
7	Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults. Transplantation and Cellular Therapy, 2021, 27, 923.e1-923.e12.	0.6	15
8	Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid Malignancy. Transplantation and Cellular Therapy, 2021, 27, 993.e1-993.e8.	0.6	4
9	Conquering the cytokine storm in COVIDâ€19â€induced ARDS using placentaâ€derived decidua stromal cells. Journal of Cellular and Molecular Medicine, 2021, 25, 10554-10564.	1.6	20
10	Expanded Hemodialysis Therapy Ameliorates Uremia-Induced Systemic Microinflammation and Endothelial Dysfunction by Modulating VEGF, TNF-Î± and AP-1 Signaling. Frontiers in Immunology, 2021, 12, 774052.	2.2	15
11	Reduced Risk of Sinusoidal Obstruction Syndrome of the Liver after Busulfanâ€Cyclophosphamide Conditioning Prior to Allogeneic Hematopoietic Stem Cell Transplantation. Clinical and Translational Science, 2020, 13, 293-300.	1.5	10
12	Treatment of radiculomyelopathy in two patients with placenta-derived decidua stromal cells. International Journal of Hematology, 2020, 111, 591-594.	0.7	4
13	Mesenchymal Stromal Cells in Pediatric Hematopoietic Cell Transplantation a Review and a Pilot Study in Children Treated With Decidua Stromal Cells for Acute Graft-versus-Host Disease. Frontiers in Immunology, 2020, 11, 567210.	2.2	11
14	Can we prevent or treat graft-versus-host disease with cellular-therapy?. Blood Reviews, 2020, 43, 100669.	2.8	13
15	Comparative Analysis of Calcineurin Inhibitorâ€“Based Methotrexate and Mycophenolate Mofetilâ€“Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 73-85.	2.0	35
16	Intravascular Mesenchymal Stromal/Stem Cell Therapy Product Diversification: Time for New Clinical Guidelines. Trends in Molecular Medicine, 2019, 25, 149-163.	3.5	288
17	Long-Term Follow-Up of a Pilot Study Using Placenta-Derived Decidua Stromal Cells for Severe Acute Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2019, 25, 1965-1969.	2.0	14
18	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Age >69 Years with Acute Myelogenous Leukemia: On Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1975-1983.	2.0	61

#	Article	IF	Citations
19	GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia. Blood Advances, 2019, 3, 1441-1449.	2.5	12
20	Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. Blood Advances, 2019, 3, 1826-1836.	2.5	89
21	Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. Blood Advances, 2019, 3, 3123-3131.	2.5	37
22	The Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Inherited Diseases Is Influenced by HLA Match, Year of Transplantation, and Immunized Female Donor. Transplantation, 2019, 103, 1247-1252.	0.5	3
23	Preclinical Toxicity Evaluation of Clinical Grade Placenta-Derived Decidua Stromal Cells. Frontiers in Immunology, 2019, 10, 2685.	2.2	20
24	Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia â€“ a matched pair analysis by the Acute Leukaemia Working Party of EBMT. British Journal of Haematology, 2019, 184, 782-787.	1.2	82
25	Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free Survival. Biology of Blood and Marrow Transplantation, 2019, 25, 270-278.	2.0	21
26	Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 362-368.	2.0	40
27	Comparable results of autologous and allogeneic haematopoietic stem cell transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia in first complete molecular remission: An analysis by the Acute Leukemia Working Party of the EBMT. European Journal of Cancer, 2018, 96, 73-81.	1.3	40
28	Placenta-Derived Decidua Stromal Cells for Treatment of Severe Acute Graft-Versus-Host Disease. Stem Cells Translational Medicine, 2018, 7, 325-331.	1.6	75
29	Tumour necrosis factor-alpha in uraemic serum promotes osteoblastic transition and calcification of vascular smooth muscle cells via extracellular signal-regulated kinases and activator protein 1/c-FOS-mediated induction of interleukin 6 expression. Nephrology Dialysis Transplantation, 2018, 33, 574-585.	0.4	56
30	Placenta-Derived Decidua Stromal Cells for Hemorrhagic Cystitis after Stem Cell Transplantation. Acta Haematologica, 2018, 139, 106-114.	0.7	28
31	Reduced intensity conditioning increases risk of severe cGVHD: identification of risk factors for cGVHD in a multicenter setting. Medical Oncology, 2018, 35, 79.	1.2	15
32	What is the outcome in patients with acute leukaemia who survive severe acute graftâ€versusâ€host disease?. Journal of Internal Medicine, 2018, 283, 166-177.	2.7	10
33	Long-term outcome in patients treated at home during the pancytopenic phase after allogeneic haematopoietic stem cell transplantation. International Journal of Hematology, 2018, 107, 478-485.	0.7	11
34	Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis. Biology of Blood and Marrow Transplantation, 2018, 24, 521-528.	2.0	34
35	Impact of HLA-G polymorphism on the outcome of allogeneic hematopoietic stem cell transplantation for metastatic renal cell carcinoma. Bone Marrow Transplantation, 2018, 53, 213-218.	1.3	8
36	Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. Blood Advances, 2018, 2, 2922-2936.	2.5	35

#	Article	IF	Citations
37	Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants. Blood Advances, 2018, 2, 1022-1031.	2.5	13
38	Cytomegalovirus-Specific CD8+ T-Cells With Different T-Cell Receptor Affinities Segregate T-Cell Phenotypes and Correlate With Chronic Graft-Versus-Host Disease in Patients Post-Hematopoietic Stem Cell Transplantation. Frontiers in Immunology, 2018, 9, 760.	2.2	12
39	Survival and Late Effects after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancy at Less than Three Years of Age. Biology of Blood and Marrow Transplantation, 2017, 23, 1327-1334.	2.0	38
40	A Preliminary Report: Radical Surgery and Stem Cell Transplantation for the Treatment of Patients With Pancreatic Cancer. Journal of Immunotherapy, 2017, 40, 132-139.	1.2	5
41	Successful treatment with placentaâ€derived decidual stromal cells in a pediatric patient with lifeâ€threatening acute gastrointestinal graftâ€versusâ€host disease. Pediatric Transplantation, 2017, 21, e12990.	0.5	4
42	GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes. Bone Marrow Transplantation, 2017, 52, 400-408.	1.3	42
43	Photochemotherapy and Graft-versus-Leukemia Reaction in Acute Leukemia: Tumor Immunity and Survival Are Dependent on Timing of Photochemotherapy of the Skin. Dermatology, 2017, 233, 303-313.	0.9	1
44	Frontline Science: Placenta-derived decidual stromal cells alter IL-2R expression and signaling in alloantigen-activated T cells. Journal of Leukocyte Biology, 2017, 101, 623-632.	1.5	14
45	Reduced intensity conditioned allograft yields favorable survival for older adults with Bâ€cell acute lymphoblastic leukemia. American Journal of Hematology, 2017, 92, 42-49.	2.0	46
46	Sequential chemotherapy followed by reducedâ€intensity conditioning and allogeneic haematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukaemia: a survey from the Acute Leukaemia Working Party of <scp>EBMT</scp>. British Journal of Haematology, 2017, 176, 431-439.	1.2	26
47	Safety and Side Effects of Using Placenta-Derived Decidual Stromal Cells for Graft-versus-Host Disease and Hemorrhagic Cystitis. Frontiers in Immunology, 2017, 8, 795.	2.2	37
48	Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Human C1q Deficiency. Transplantation, 2016, 100, 1356-1362.	0.5	30
49	Improved overall survival for pediatric patients undergoing allogeneic hematopoietic stem cell transplantation â€“ A comparison of the last two decades. Pediatric Transplantation, 2016, 20, 667-674.	0.5	26
50	The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes. Haematologica, 2016, 101, 1426-1433.	1.7	53
51	Photochemotherapy of Cutaneous Graft-versus-Host Disease May Reduce Concomitant Visceral Disease. Dermatology, 2016, 232, 453-463.	0.9	2
52	A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation. Haematologica, 2016, 101, 1417-1425.	1.7	61
53	Cryopreserved or Fresh Mesenchymal Stromal Cells: Only a Matter of Taste or Key to Unleash the Full Clinical Potential of MSC Therapy?. Advances in Experimental Medicine and Biology, 2016, 951, 77-98.	0.8	141
54	Intra-arterial Administration of Placenta-Derived Decidual Stromal Cells to the Superior Mesenteric Artery in the Rabbit: Distribution of Cells, Feasibility, and Safety. Cell Transplantation, 2016, 25, 401-410.	1.2	12

#	Article	IF	Citations
55	Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. Biology of Blood and Marrow Transplantation, 2016, 22, 248-257.	2.0	33
56	Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis. Lancet Haematology,the, 2016, 3, e45-e52.	2.2	158
57	Long-Term Follow-Up of Allogeneic Hematopoietic Stem Cell Transplantation for Solid Cancer. Biology of Blood and Marrow Transplantation, 2016, 22, 676-681.	2.0	9
58	Is there a stronger graft-versus-leukemia effect using HLA-haploidentical donors compared with HLA-identical siblings?. Leukemia, 2016, 30, 447-455.	3.3	85
59	Both high and low levels of cellular Epstein-Barr virus DNA in blood identify failure after hematologic stem cell transplantation in conjunction with acute GVHD and type of conditioning. Oncotarget, 2016, 7, 30230-30240.	0.8	13
60	Quality of the hematopoietic stem cell graft affects the clinical outcome of allogeneic stem cell transplantation. Transfusion, 2015, 55, 2339-2350.	0.8	23
61	Bone marrow aspiration technique has deteriorated in recent years. Bone Marrow Transplantation, 2015, 50, 1007-1009.	1.3	22
62	Effect of Total Nucleated and CD34+ Cell Dose on Outcome after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 889-893.	2.0	106
63	Immunogenicity of Decidual Stromal Cells in an Epidermolysis Bullosa Patient and in Allogeneic Hematopoietic Stem Cell Transplantation Patients. Stem Cells and Development, 2015, 24, 1471-1482.	1.1	20
64	The relationship between oral mucositis and levels of pro-inflammatory cytokines in serum and in gingival crevicular fluid in allogeneic stem cell recipients. Supportive Care in Cancer, 2015, 23, 1749-1757.	1.0	11
65	Different Procoagulant Activity of Therapeutic Mesenchymal Stromal Cells Derived from Bone Marrow and Placental Decidua. Stem Cells and Development, 2015, 24, 2269-2279.	1.1	104
66	Mesenchymal stem (stromal) cells for treatment of acute respiratory distress syndrome. Lancet Respiratory Medicine,the, 2015, 3, e12.	5.2	9
67	Impact of KIR and HLA Genotypes on Outcomes after Reduced-Intensity Conditioning Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 1589-1596.	2.0	37
68	Haematopoietic stem cell transplantation for refractory Langerhans cell histiocytosis: outcome by intensity of conditioning. British Journal of Haematology, 2015, 169, 711-718.	1.2	56
69	Xeno-immunosuppressive properties of human decidual stromal cells in mouse models of alloreactivity inÂvitro and inÂvivo. Cytotherapy, 2015, 17, 1732-1745.	0.3	17
70	Treatment of Severe Chronic Graft-Versus-Host Disease with Decidual Stromal Cells and Tracing with ¹¹¹Indium Radiolabeling. Stem Cells and Development, 2015, 24, 253-263.	1.1	47
71	Twenty-year follow-up of a randomized trial comparing intraosseous and i.v. BM transplantation. Bone Marrow Transplantation, 2014, 49, 1541-1542.	1.3	6
72	Hematopoietic SCT: a useful treatment for late metachromatic leukodystrophy. Bone Marrow Transplantation, 2014, 49, 1046-1051.	1.3	44

#	Article	IF	Citations
73	Superselective intra-arterial umbilical cord blood administration to BM in experimental animals. Bone Marrow Transplantation, 2014, 49, 1486-1491.	1.3	2
74	Home care during neutropenia after allogeneic hematopoietic stem cell transplantation in children and adolescents is safe and may be more advantageous than isolation in hospital. Pediatric Transplantation, 2014, 18, 398-404.	0.5	9
75	TCR+CD4â˜'CD8â˜' T cells in Antigen-specific MHC Class Iâ€"restricted T-cell Responses After Allogeneic Hematopoietic Stem Cell Transplantation. Journal of Immunotherapy, 2014, 37, 416-425.	1.2	7
76	Who Is the Best Hematopoietic Stem-Cell Donor for a Male Patient With Acute Leukemia?. Transplantation, 2014, 98, 569-577.	0.5	11
77	Prophylaxis and treatment of GVHD: EBMTâ€"ELN working group recommendations for a standardized practice. Bone Marrow Transplantation, 2014, 49, 168-173.	1.3	252
78	Stromal cellsâ€"are they really useful for GVHD?. Bone Marrow Transplantation, 2014, 49, 737-743.	1.3	32
79	Improved Survival with Ursodeoxycholic Acid Prophylaxis in Allogeneic Stem Cell Transplantation: Long-Term Follow-Up of a Randomized Study. Biology of Blood and Marrow Transplantation, 2014, 20, 135-138.	2.0	58
80	Analysis of Donor and Recipient ABO Incompatibility and Antibody-Associated Complications after Allogeneic Stem Cell Transplantation with Reduced-Intensity Conditioning. Biology of Blood and Marrow Transplantation, 2014, 20, 264-271.	2.0	41
81	Second Solid Cancers after Allogeneic Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning. Biology of Blood and Marrow Transplantation, 2014, 20, 1777-1784.	2.0	50
82	Reduced plasma levels of soluble interleukin-7 receptor during graft-versus-host disease (GVHD) in children and adults. BMC Immunology, 2014, 15, 25.	0.9	13
83	Reduced intensity conditioning and oral care measures prevent oral mucositis and reduces days of hospitalization in allogeneic stem cell transplantation recipients. Supportive Care in Cancer, 2014, 22, 2133-2140.	1.0	32
84	Effect of Postremission Therapy before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission. Biology of Blood and Marrow Transplantation, 2014, 20, 202-208.	2.0	33
85	Posaconazole Concentrations in Human Tissues after Allogeneic Stem Cell Transplantation. Antimicrobial Agents and Chemotherapy, 2014, 58, 4941-4943.	1.4	19
86	Low CD34 Dose Is Associated with Poor Survival after Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation, 2014, 20, 1418-1425.	2.0	40
87	Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation. Haematologica, 2014, 99, 346-352.	1.7	153
88	HLA-C expression levels define permissible mismatches in hematopoietic cell transplantation. Blood, 2014, 124, 3996-4003.	0.6	146
89	Pre-Transplant C-Reactive Protein (CRP), Ferritin and Albumin As Biomarkers to Predict Transplant Related Mortality (TRM) after Allogeneic Hematopoietic Cell Transplant (HCT). Blood, 2014, 124, 422-422.	0.6	6
90	Survival after T-Cell Replete Haplo-Identical Related Donor Transplant Using Post-Transplant Cyclophosphamide Compared with Matched Unrelated Donor Transplant for Acute Myeloid Leukemia. Blood, 2014, 124, 679-679.	0.6	8

#	Article	IF	Citations
91	Human C1q Deficiency and Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2014, 124, 5922-5922.	0.6	0
92	Many Days at Home during Neutropenia after Allogeneic Hematopoietic Stem Cell Transplantation Correlates with Low Incidence of Acute Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2013, 19, 314-320.	2.0	22
93	Fetal Membrane Cells for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease. Stem Cells, 2013, 31, 592-601.	1.4	84
94	Mesenchymal Stem Cells for Treatment and Prevention of Graft-Versus-Host Disease and Graft Failure After Hematopoietic Stem Cell Transplantation and Future Challenges. , 2013, , 173-205.		4
95	Decidual Stromal Cells Promote Regulatory T Cells and Suppress Alloreactivity in a Cell Contact-Dependent Manner. Stem Cells and Development, 2013, 22, 2596-2605.	1.1	73
96	Graft failure in the modern era of allogeneic hematopoietic SCT. Bone Marrow Transplantation, 2013, 48, 537-543.	1.3	223
97	Increased risk of gastrointestinal acute <scp>GVHD</scp> following the addition of melphalan to busulfan/cyclophosphamide conditioning. Pediatric Transplantation, 2013, 17, 285-293.	0.5	14
98	A prospective randomized toxicity study to compare reducedâ€intensity and myeloablative conditioning in patients with myeloid leukaemia undergoing allogeneic haematopoietic stem cell transplantation. Journal of Internal Medicine, 2013, 274, 153-162.	2.7	42
99	A high antithymocyte globulin dose increases the risk of relapse after reduced intensity conditioning <scp>HSCT</scp> with unrelated donors. Clinical Transplantation, 2013, 27, E368-74.	0.8	50
100	Graft Failure In Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2013, 122, 4559-4559.	0.6	0
101	Increased costs after allogeneic haematopoietic SCT are associated with major complications and re-transplantation. Bone Marrow Transplantation, 2012, 47, 706-715.	1.3	45
102	Effect of acute and chronic GVHD on relapse and survival after reduced-intensity conditioning allogeneic transplantation for myeloma. Bone Marrow Transplantation, 2012, 47, 831-837.	1.3	31
103	Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplantation, 2012, 47, 203-211.	1.3	245
104	Factors With an Impact on Chimerism Development and Long-Term Survival After Umbilical Cord Blood Transplantation. Transplantation, 2012, 94, 1066-1074.	0.5	20
105	Treatment with mesenchymal stromal cells is a risk factor for pneumoniaâ€related death after allogeneic hematopoietic stem cell transplantation. European Journal of Haematology, 2012, 89, 220-227.	1.1	69
106	Treatment of severe acute graft-versus-host disease with mesenchymal stromal cells: a comparison with non-MSC treated patients. International Journal of Hematology, 2012, 96, 822-824.	0.7	35
107	Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study. Lancet Oncology, The, 2012, 13, 366-374.	5.1	289
108	Is Graft-versus-Leukemia More Effective Using Reduced-Intensity Conditioning Compared with Myeloablative Conditioning?. Biology of Blood and Marrow Transplantation, 2012, 18, 1615-1617.	2.0	2

#	Article	IF	Citations
109	Long-Term Complications, Immunologic Effects, and Role of Passage for Outcome in Mesenchymal Stromal Cell Therapy. Biology of Blood and Marrow Transplantation, 2012, 18, 557-564.	2.0	282
110	Are Therapeutic Human Mesenchymal Stromal Cells Compatible with Human Blood?. Stem Cells, 2012, 30, 1565-1574.	1.4	281
111	Analysis of Tissues Following Mesenchymal Stromal Cell Therapy in Humans Indicates Limited Long-Term Engraftment and No Ectopic Tissue Formation. Stem Cells, 2012, 30, 1575-1578.	1.4	456
112	Different impact of intermediate and unfavourable cytogenetics at the time of diagnosis on outcome of de novo AML after allo-SCT: a long-term retrospective analysis from a single institution. Medical Oncology, 2012, 29, 2348-2358.	1.2	3
113	Growth factorâ€associated graftâ€versusâ€host disease and mortality 10Âyears after allogeneic bone marrow transplantation. British Journal of Haematology, 2012, 157, 220-229.	1.2	5
114	Stromal cells from term fetal membrane are highly suppressive in allogeneic settings in vitro. Clinical and Experimental Immunology, 2012, 167, 543-555.	1.1	89
115	Bone marrow or peripheral blood stem cell transplantation from unrelated donors in adult patients with acute myeloid leukaemia, an Acute Leukaemia Working Party analysis in 2262 patients. Journal of Internal Medicine, 2012, 272, 472-483.	2.7	32
116	Disturbances in dental development and craniofacial growth in children treated with hematopoietic stem cell transplantation. Orthodontics and Craniofacial Research, 2012, 15, 21-29.	1.2	26
117	Co-infusion of ex vivo-expanded, parental MSCs prevents life-threatening acute GVHD, but does not reduce the risk of graft failure in pediatric patients undergoing allogeneic umbilical cord blood transplantation. Bone Marrow Transplantation, 2011, 46, 200-207.	1.3	154
118	Mesenchymal stem cells for treatment of acute and chronic graft-versus-host disease, tissue toxicity and hemorrhages. Best Practice and Research in Clinical Haematology, 2011, 24, 65-72.	0.7	81
119	One-Antigen Mismatched Related versus HLA-Matched Unrelated Donor Hematopoietic Stem Cell Transplantation in Adults with Acute Leukemia: Center for International Blood and Marrow Transplant Research Results in the Era of Molecular HLA Typing. Biology of Blood and Marrow Transplantation, 2011, 17, 640-648.	2.0	55
120	Improved Survival after Allogeneic Hematopoietic Stem Cell Transplantation in Recent Years. A Single-Center Study. Biology of Blood and Marrow Transplantation, 2011, 17, 1688-1697.	2.0	131
121	Mesenchymal Stromal Cells Engage Complement and Complement Receptor Bearing Innate Effector Cells to Modulate Immune Responses. PLoS ONE, 2011, 6, e21703.	1.1	135
122	Second allogeneic hematopoietic stem cell transplantation: a treatment for graft failure. Clinical Transplantation, 2011, 25, E68-E76.	0.8	37
123	Longâ€term salivary function after conditioning with busulfan, fractionated or singleâ€dose TBI. Oral Diseases, 2011, 17, 670-676.	1.5	10
124	Mesenchymal stromal cells as treatment for chronic GVHD. Bone Marrow Transplantation, 2011, 46, 163-164.	1.3	24
125	Sirolimus and tacrolimus as immune prophylaxis compared to cyclosporine with or without methotrexate in patients undergoing allogeneic haematopoietic stem cell transplantation for non-malignant disorders. European Journal of Haematology, 2011, 87, 503-509.	1.1	24
126	Xerostomia in children and adolescents after stem cell transplantation conditioned with total body irradiation or busulfan. Oral Oncology, 2011, 47, 915-919.	0.8	13

#	Article	IF	Citations
127	Hematopoietic stem cell transplantation in severe congenital neutropenia. Pediatric Blood and Cancer, 2011, 56, 444-451.	0.8	34
128	Pooled MSCs for treatment of severe hemorrhage. Bone Marrow Transplantation, 2011, 46, 1158-1160.	1.3	19
129	Granulocyte Colony-Stimulating Factor Induced Acute and Chronic Graft-Versus-Host Disease. Transplantation, 2010, 90, 1022-1029.	0.5	29
130	Advancement of Mesenchymal Stem Cell Therapy in Solid Organ Transplantation (MISOT). Transplantation, 2010, 90, 124-126.	0.5	66
131	Impact of age on outcomes after bone marrow transplantation for acquired aplastic anemia using HLA-matched sibling donors. Haematologica, 2010, 95, 2119-2125.	1.7	137
132	Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors. Blood, 2010, 116, 4007-4015.	0.6	105
133	GVHD prophylaxis using lowâ€dose cyclosporine improves survival in leukaemic recipients of HLAâ€identical sibling transplants. European Journal of Haematology, 2010, 84, 323-331.	1.1	14
134	Leukemia Lineage-Specific Chimerism Analysis andÂMolecular Monitoring Improve Outcome of Donor Lymphocyte Infusions. Biology of Blood and Marrow Transplantation, 2010, 16, 1728-1737.	2.0	25
135	Reduced Intensity Conditioning Compared With Myeloablative Conditioning Using Unrelated Donor Transplants in Patients With Acute Myeloid Leukemia. Journal of Clinical Oncology, 2009, 27, 4570-4577.	0.8	238
136	The allogeneic graftâ€versusâ€cancer effect. British Journal of Haematology, 2009, 147, 614-633.	1.2	132
137	A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allo-SCT. Bone Marrow Transplantation, 2009, 43, 553-561.	1.3	106
138	Pediatric Transplantation: Ten years on. Pediatric Transplantation, 2009, 13, 272-277.	0.5	6
139	Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation in Metastatic Colorectal Cancer as a Novel Adoptive Cell Therapy Approach. The European Group for Blood and Marrow Transplantation Experience. Biology of Blood and Marrow Transplantation, 2009, 15, 326-335.	2.0	27
140	Lymphocyte Recovery Is a Major Determinant of Outcome after Matched Unrelated Myeloablative Transplantation for Myelogenous Malignancies. Biology of Blood and Marrow Transplantation, 2009, 15, 1108-1115.	2.0	100
141	Mesenchymal Stromal Cells as First-Line Treatment of Graft Failure After Hematopoietic Stem Cell Transplantation. Stem Cells and Development, 2009, 18, 1243-1246.	1.1	14
142	Optimizing in vitro conditions for immunomodulation and expansion of mesenchymal stromal cells. Cytotherapy, 2009, 11, 129-136.	0.3	69
143	HSCT Recipients Have Specific Tolerance to MSC but not to the MSC Donor. Journal of Immunotherapy, 2009, 32, 755-764.	1.2	51
144	Increased Frequency and Responsiveness of PSA-Specific T Cells After Allogeneic Hematopoetic Stem-Cell Transplantation. Transplantation, 2009, 87, 467-472.	0.5	2

#	Article	IF	Citations
145	The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood, 2009, 113, 3110-3118.	0.6	147
146	Comparison of Outcomes After Unrelated Cord Blood Transplantation and Matched Unrelated Donor RIC Transplantation for Lymphoid Malignancies - A Eurocord-Netcord Group/ Lymphoma Working Party and Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation Study.. Blood, 2009, 114, 663-663.	0.6	24
147	Comparison of Busulfan and Cyclophosphamide (Bu-Cy)-Based Standard Myeloablative Conditioning (MAC) Vs. Fludarabine and Busulfan (Flu-Bu)-Based Reduced-Intensity Conditioning (RIC) Prior to Allogeneic Stem Cell Transplantation (allo-SCT) From An HLA Identical Sibling Donor for Acute Myeloid Leukemia (AML) Patients in First Complete Remission (CR1) Aged >40 Years: a Retrospective Analysis From the Acute Leukemia Working Party of EBMT.. Blood, 2009, 114, 3264-3264.	0.6	0
148	Long-Term Survival and Late Deaths After Hematopoietic Stem Cell Transplantation for Primary Immunodeficiency Diseases and Inborn Errors of Metabolism.. Blood, 2009, 114, 3320-3320.	0.6	0
149	Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Myeloma (MM) - Chronic Graft Versus Host Disease (GVHD) is Associated with Lower Risk of Relapse and Superior Progression Free Survival (PFS) - A CIBMTR Analysis.. Blood, 2009, 114, 53-53.	0.6	1
150	Unrelated cord blood and mismatched unrelated volunteer donor transplants, two alternatives in patients who lack an HLA-identical donor. Bone Marrow Transplantation, 2008, 42, 643-648.	1.3	37
151	Risk factors for acute graft-versus-host disease grades IIâ€“IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donorsâ€”a single centre study. Bone Marrow Transplantation, 2008, 41, 399-405.	1.3	29
152	BK-viruria and haemorrhagic cystitis are more frequent in allogeneic haematopoietic stem cell transplant patients receiving full conditioning and unrelated-HLA-mismatched grafts. Bone Marrow Transplantation, 2008, 41, 737-742.	1.3	79
153	Outcome of haematopoietic stem cell transplantation in patients transplanted with matched unrelated donors vs alleleâ€mismatched donors: a single centre study. Tissue Antigens, 2008, 72, 549-558.	1.0	17
154	Genomic tissue typing and optimal antithymocyte globuline dose using unrelated donors results in similar survival and relapse as HLA-identical siblings in haematopoietic stem-cell transplantation for leukaemia. European Journal of Haematology, 2008, 80, 419-428.	1.1	16
155	A Phase 3, Randomized, Placeboâ€controlled Trial of Filgrastim in Patients with Haematological Malignancies Undergoing Matchedâ€related Allogeneic Bone Marrow Transplantation. Archives of Drug Information, 2008, 1, 89-96.	1.6	12
156	Graft Failure after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2008, 14, 165-170.	2.0	162
157	Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet, The, 2008, 371, 1579-1586.	6.3	2,474
158	No increased trapping of multipotent mesenchymal stromal cells in bone marrow filters compared with other bone marrow cells. Cytotherapy, 2008, 10, 238-242.	0.3	7
159	Risk Factors for Acute Graft-Versus-Host Disease After Human Leukocyte Antigenâ€Identical Sibling Transplants for Adults With Leukemia. Journal of Clinical Oncology, 2008, 26, 5728-5734.	0.8	159
160	Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses. Blood, 2008, 112, 532-541.	0.6	149
161	Case-Control Comparison of At-Home and Hospital Care for Allogeneic Hematopoietic Stem-Cell Transplantation: The Role of Oral Nutrition. Transplantation, 2008, 85, 1000-1007.	0.5	37
162	Similar Outcomes Using Myeloablative Versus Reduced Intensity and Non-Myeloablative Allogeneic Transplant Preparative Regimens for AML or MDS: From the Center for International Blood and Marrow Transplant Research. Blood, 2008, 112, 348-348.	0.6	9

#	Article	IF	Citations
163	The importance of HLA-DPB1 in unrelated donor hematopoietic cell transplantation. Blood, 2007, 110, 4560-4566.	0.6	166
164	Generation of Immunosuppressive Mesenchymal Stem Cells in Allogeneic Human Serum. Transplantation, 2007, 84, 1055-1059.	0.5	57
165	Similar Outcome After Unrelated Allogeneic Peripheral Blood Stem Cell Transplantation Compared With Bone Marrow in Children and Adolescents. Transplantation, 2007, 84, 551-554.	0.5	17
166	Immunotherapy by Allogeneic Stem Cell Transplantation. Advances in Cancer Research, 2007, 97, 25-60.	1.9	28
167	Fludarabine-based disease-specific conditioning or conventional myeloablative conditioning in hematopoietic stem cell transplantation for treatment of non-malignant diseases. Bone Marrow Transplantation, 2007, 39, 383-388.	1.3	19
168	Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia, 2007, 21, 1733-1738.	3.3	406
169	Tissue repair using allogeneic mesenchymal stem cells for hemorrhagic cystitis, pneumomediastinum and perforated colon. Leukemia, 2007, 21, 2271-2276.	3.3	193
170	Hemorrhagic cystitis: a retrospective single-center survey. Clinical Transplantation, 2007, 21, 659-667.	0.8	59
171	Immunomodulation by mesenchymal stem cells and clinical experience. Journal of Internal Medicine, 2007, 262, 509-525.	2.7	648
172	Mesenchymal Stem Cells Stimulate Antibody Secretion in Human B Cells. Scandinavian Journal of Immunology, 2007, 65, 336-343.	1.3	261
173	Relapse of preB-ALL after rituximab treatment for chronic graft versus host disease. Implications for its use?. Medical Oncology, 2007, 24, 354-356.	1.2	5
174	Recent Decrease in Acute GVHD and Increased Relapse in Children with Leukemia Receiving Unrelated Donor Bone Marrow Transplants.. Blood, 2007, 110, 1081-1081.	0.6	0
175	Mesenchymal Stem Cells Combined with Cyclosporine Inhibits Cytotoxic T Cells. Biology of Blood and Marrow Transplantation, 2006, 12, 693-694.	2.0	14
176	KIR Ligands and Prediction of Relapse after Unrelated Donor Hematopoietic Cell Transplantation for Hematologic Malignancy. Biology of Blood and Marrow Transplantation, 2006, 12, 828-836.	2.0	201
177	Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation. Blood, 2006, 107, 1712-1716.	0.6	85
178	Costs of Allogeneic Hematopoietic Stem Cell Transplantation. Transplantation, 2006, 82, 147-153.	0.5	48
179	Allogeneic Hematopoietic Stem Cell Transplantation for Inherited Disorders: Experience in a Single Center. Transplantation, 2006, 81, 718-725.	0.5	59
180	Treatment Costs and Survival in Patients with Grades III-IV Acute Graft-Versus-Host Disease after Allogenic Hematopoietic Stem Cell Transplantation During Three Decades. Transplantation, 2006, 81, 1600-1603.	0.5	18

#	Article	IF	Citations
181	Mesenchymal stem cells are susceptible to human herpesviruses, but viral DNA cannot be detected in the healthy seropositive individual. Bone Marrow Transplantation, 2006, 37, 1051-1059.	1.3	88
182	Myeloablative conditioning for hematopoietic stem-cell transplantation in patients with non-malignant diseases. Bone Marrow Transplantation, 2006, 38, 321-322.	1.3	2
183	Mesenchymal stem cells: properties and role in clinical bone marrow transplantation. Current Opinion in Immunology, 2006, 18, 586-591.	2.4	202
184	Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. Annals of Oncology, 2006, 17, 1134-1140.	0.6	84
185	Mesenchymal Stem Cells for Treatment of Therapy-Resistant Graft-versus-Host Disease. Transplantation, 2006, 81, 1390-1397.	0.5	1,003
186	Mesenchymal Stem Cells for Treatment of Severe Acute Graft-Versus-Host Disease.. Blood, 2006, 108, 2918-2918.	0.6	4
187	Mesenchymal Stem Cells for Treatment of Severe Acute Graft-Versus-Host Disease.. Blood, 2006, 108, 5304-5304.	0.6	8
188	The incidence of hemorrhagic cystitis and BK-viruria in allogeneic hematopoietic stem cell recipients according to intensity of the conditioning regimen. Haematologica, 2006, 91, 401-4.	1.7	87
189	The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation. Haematologica, 2006, 91, 1059-67.	1.7	89
190	Fetal Mesenchymal Stem-Cell Engraftment in Bone after In Utero Transplantation in a Patient with Severe Osteogenesis Imperfecta. Transplantation, 2005, 79, 1607-1614.	0.5	397
191	Increased risk of extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation using unrelated donors. Blood, 2005, 105, 548-551.	0.6	70
192	A prospective randomized trial of a prophylactic platelet transfusion trigger of 10 x 109 per L versus 30 x 109 per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion, 2005, 45, 1064-1072.	0.8	95
193	Long-term follow-up of patients treated at home during the pancytopenic phase after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplantation, 2005, 36, 511-516.	1.3	38
194	Allogeneic hematopoietic stem cell transplantation: state of the art and new perspectives. Apmis, 2005, 113, 813-830.	0.9	60
195	Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Experimental Cell Research, 2005, 305, 33-41.	1.2	448
196	Introduction to graft-versus-host disease. Biology of Blood and Marrow Transplantation, 2005, 11, 17-20.	2.0	8
197	Immunobiology of Human Mesenchymal Stem Cells and Future Use in Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2005, 11, 321-334.	2.0	429
198	Fatal Infectious Complications Developing Late after Allogeneic Stem Cell Transplantation.. Blood, 2005, 106, 3239-3239.	0.6	0

#	Article	IF	Citations
199	Treatment With Granulocyte Colony-Stimulating Factor After Allogeneic Bone Marrow Transplantation for Acute Leukemia Increases the Risk of Graft-Versus-Host Disease and Death: A Study From the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Journal of Clinical Oncology, 2004, 22, 416-423.	0.8	173
200	Outcome of Allogeneic Hematopoietic Stem-Cell Transplantation in Adult Patients With Acute Lymphoblastic Leukemia: No Difference in Related Compared With Unrelated Transplant in First Complete Remission. Journal of Clinical Oncology, 2004, 22, 2816-2825.	0.8	193
201	Higher Mortality After Allogeneic Peripheral-Blood Transplantation Compared With Bone Marrow in Children and Adolescents: The Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. Journal of Clinical Oncology, 2004, 22, 4872-4880.	0.8	246
202	Which donor should be chosen for hematopoietic stem cell transplantation among unrelated HLA-A, -B, and -DRB1 genomically identical volunteers?. Biology of Blood and Marrow Transplantation, 2004, 10, 128-134.	2.0	46
203	Graft-versus-host disease is associated with a lower relapse incidence after hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia. Biology of Blood and Marrow Transplantation, 2004, 10, 195-203.	2.0	53
204	Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet, The, 2004, 363, 1439-1441.	6.3	2,534
205	A Comparison of Nonmyeloablative and Reduced-Intensity Conditioning for Allogeneic Stem-Cell Transplantation. Transplantation, 2004, 78, 1014-1020.	0.5	59
206	Dose Study of Thymoglobulin During Conditioning for Unrelated Donor Allogeneic Stem-Cell Transplantation. Transplantation, 2004, 78, 122-127.	0.5	153
207	Indiumâ€“111-Labelled Donor-Lymphocyte Infusion by way of Hepatic Artery and Radio-Frequency Ablation against Liver Metastases of Renal and Colon Carcinoma after Allogeneic Hematopoietic Stem-Cell Transplantation. Transplantation, 2004, 78, 697-703.	0.5	12
208	Increased Infection-Related Mortality in KIR-Ligandâ€“Mismatched Unrelated Allogeneic Hematopoietic Stem-Cell Transplantation. Transplantation, 2004, 78, 1081-1085.	0.5	81
209	Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation. Transplantation, 2004, 78, 122-7.	0.5	109
210	HLA expression and immunologic propertiesof differentiated and undifferentiated mesenchymal stem cells. Experimental Hematology, 2003, 31, 890-896.	0.2	1,510
211	Roles of HLA-B, HLA-C and HLA-DPA1 incompatibilities in the outcome of unrelated stem-cell transplantation. Tissue Antigens, 2003, 62, 243-250.	1.0	72
212	Mesenchymal Stem Cells Inhibit and Stimulate Mixed Lymphocyte Cultures and Mitogenic Responses Independently of the Major Histocompatibility Complex. Scandinavian Journal of Immunology, 2003, 57, 11-20.	1.3	1,274
213	Decreased treatment failure in recipients of HLA-identical bone marrow or peripheral blood stem cell transplants with high CD34 cell doses. British Journal of Haematology, 2003, 121, 874-885.	1.2	77
214	Minimal residual disease detection after allogeneic stem cell transplantation is correlated to relapse in patients with acute lymphoblastic leukaemia. British Journal of Haematology, 2003, 122, 788-794.	1.2	42
215	Patients with acute lymphoblastic leukaemia allografted with a matched unrelated donor may have a lower survival with a peripheral blood stem cell graft compared to bone marrow. Bone Marrow Transplantation, 2003, 31, 23-29.	1.3	49
216	Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. Bone Marrow Transplantation, 2003, 31, 253-261.	1.3	134

#	Article	IF	Citations
217	G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD Ilâ€“IV. Bone Marrow Transplantation, 2003, 32, 217-223.	1.3	60
218	Liver transplantation followed by adjuvant nonmyeloablative hemopoietic stem cell transplantation for advanced primary liver cancer in humans1. Transplantation, 2003, 75, 1061-1066.	0.5	18
219	Engraftment and tumor formation after allogeneic in utero transplantation of primate embryonic stem cells.. Transplantation, 2003, 76, 1011-1012.	0.5	12
220	Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation, 2003, 76, 1208-1213.	0.5	571
221	Association between pretransplant Thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors. Bone Marrow Transplantation, 2002, 29, 391-397.	1.3	74
222	Relevance of Bone Marrow Cell Dose on Allogeneic Transplantation Outcomes for Patients With Acute Myeloid Leukemia in First Complete Remission: Results of a European Survey. Journal of Clinical Oncology, 2002, 20, 4324-4330.	0.8	65
223	Ten years' experience with liposomal amphotericin B in transplant recipients at Huddinge University Hospital. Journal of Antimicrobial Chemotherapy, 2002, 49, 51-55.	1.3	8
224	Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood, 2002, 100, 406-414.	0.6	503
225	Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood, 2002, 100, 1977-1983.	0.6	232
226	Home care during the pancytopenic phase after allogeneic hematopoietic stem cell transplantation is advantageous compared with hospital care. Blood, 2002, 100, 4317-4324.	0.6	139
227	Transplantation of Peripheral Blood Stem Cells as Compared With Bone Marrow From HLA-Identical Siblings in Adult Patients With Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2002, 20, 4655-4664.	0.8	136
228	The graft-versus-leukaemia effect in haematopoietic stem cell transplantation using unrelated donors. Bone Marrow Transplantation, 2002, 30, 761-768.	1.3	23
229	The role of disease stage in the response to donor lymphocyte infusions as treatment for leukemic relapse. Biology of Blood and Marrow Transplantation, 2001, 7, 31-38.	2.0	47
230	No Disadvantage in Outcome of Using Matched Unrelated Donors as Compared With Matched Sibling Donors for Bone Marrow Transplantation in Children With Acute Lymphoblastic Leukemia in Second Remission. Journal of Clinical Oncology, 2001, 19, 3406-3414.	0.8	92
231	No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors. Blood, 2001, 98, 1739-1745.	0.6	108
232	The significance of graft-versus-host disease and pretransplantation minimal residual disease status to outcome after allogeneic stem cell transplantation in patients with acute lymphoblastic leukemia. Blood, 2001, 98, 1982-1985.	0.6	87
233	Treatment of severe acute graft-versus-host disease with anti-thymocyte globulin. Clinical Transplantation, 2001, 15, 147-153.	0.8	71
234	A graft-versus-colonic cancer effect of allogeneic stem cell transplantation. Bone Marrow Transplantation, 2001, 28, 1161-1166.	1.3	28

#	Article	IF	Citations
235	Leukemia lineage-specific chimerism analysis is a sensitive predictor of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplantation. Leukemia, 2001, 15, 1976-1985.	3.3	120
236	T CELL MIXED CHIMERISM IS SIGNIFICANTLY CORRELATED TO A DECREASED RISK OF ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION 1. Transplantation, 2001, 71, 433-439.	0.5	88
237	The dismal outcome in patients with acute leukaemia who relapse after an autograft is improved if a second autograft or a matched allograft is performed. Bone Marrow Transplantation, 2000, 25, 1053-1058.	1.3	31
238	Is it safe to treat allogeneic stem cell transplant recipients at home during the pancytopenic phase? A pilot trial. Bone Marrow Transplantation, 2000, 26, 1057-1060.	1.3	28
239	Minimal residual disease is common after allogeneic stem cell transplantation in patients with B cell chronic lymphocytic leukemia and may be controlled by graft-versus-host disease. Leukemia, 2000, 14, 247-254.	3.3	63
240	Response to Dr Furebring. Bone Marrow Transplantation, 2000, 25, 342-343.	1.3	3
241	Mixed chimerism in the B cell lineage is a rapid and sensitive indicator of minimal residual disease in bone marrow transplant recipients with pre-B cell acute lymphoblastic leukemia. Bone Marrow Transplantation, 2000, 25, 843-851.	1.3	71
242	Faster engraftment of neutrophils and platelets with peripheral blood stem cells from unrelated donors: a comparison with marrow transplantation. Bone Marrow Transplantation, 2000, 25, S6-S8.	1.3	25
243	N-acetylcysteine for hepatic veno-occlusive disease after allogeneic stem cell transplantation. Bone Marrow Transplantation, 2000, 25, 993-996.	1.3	70
244	High levels of human herpesvirus 6 DNA in peripheral blood leucocytes are correlated to platelet engraftment and disease in allogeneic stem cell transplant patients. British Journal of Haematology, 2000, 111, 774-781.	1.2	65
245	Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood, 2000, 95, 807-814.	0.6	315
246	Is there a graft-versus-leukaemia effect in the absence of graft-versus-host disease in patients undergoing bone marrow transplantation for acute leukaemia?. British Journal of Haematology, 2000, 111, 1130-1137.	1.2	63
247	TRANSPLANTATION OF AUTOLOGOUS AND ALLOGENEIC BONE MARROW WITH LIVER FROM A CADAVERIC DONOR FOR PRIMARY LIVER CANCER1. Transplantation, 2000, 69, 2043-2048.	0.5	30
248	Effect of nucleated marrow cell dose on relapse and survival in identical twin bone marrow transplants for leukemia. Blood, 2000, 95, 3323-7.	0.6	69
249	Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood, 2000, 95, 3702-9.	0.6	378
250	Allogeneic bone marrow transplant or second autograft in patients with acute leukemia who relapse after an autograft. Bone Marrow Transplantation, 1999, 24, 389-396.	1.3	39
251	Low-dose cyclosporine of short duration increases the risk of mild and moderate GVHD and reduces the risk of relapse in HLA-identical sibling marrow transplant recipients with leukaemia. Bone Marrow Transplantation, 1999, 24, 629-635.	1.3	50
252	Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation. Bone Marrow Transplantation, 1999, 24, 823-830.	1.3	120

#	Article	IF	Citations
253	A prospective randomized trial of Filgrastim (r-metHuG-CSF) given at different times after unrelated bone marrow transplantation. Bone Marrow Transplantation, 1999, 24, 831-836.	1.3	46
254	Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplantation Group. Blood, 1999, 93, 2196-201.	0.6	62
255	Peripheral blood stem cell transplantation from unrelated donors: a comparison with marrow transplantation. Blood, 1999, 94, 455-64.	0.6	42
256	Transplantation with unrelated bone marrow in leukaemic patients above 40 years of age. Bone Marrow Transplantation, 1998, 21, 43-49.	1.3	26
257	Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplantation, 1998, 21, 995-1003.	1.3	240
258	Bacteraemia during the aplastic phase after allogeneic bone marrow transplantation is associated with early death from invasive fungal infection. Bone Marrow Transplantation, 1998, 22, 795-800.	1.3	80
259	Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. Bone Marrow Transplantation, 1998, 22, 755-761.	1.3	176
260	Increased serum concentrations of interleukin-2 receptor in the first trimester in women who later developed severe preeclampsia. Acta Obstetricia Et Gynecologica Scandinavica, 1998, 77, 591-593.	1.3	33
261	LOW INCIDENCE OF ACUTE GRAFT-VERSUS-HOST DISEASE, USING UNRELATED HLA-A-, HLA-B-, AND HLA-DR-COMPATIBLE DONORS AND CONDITIONING, INCLUDING ANTI-T-CELL ANTIBODIES1. Transplantation, 1998, 66, 620-625.	0.5	63
262	RESULTS OF DIFFERENT STRATEGIES FOR REDUCING CYTOMEGALOVIRUS-ASSOCIATED MORTALITY IN ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS1. Transplantation, 1998, 66, 1330-1334.	0.5	150
263	Faster engraftment of peripheral blood progenitor cells compared to bone marrow from unrelated donors. Bone Marrow Transplantation, 1998, 21 Suppl 3, S81-4.	1.3	1
264	Allogeneic Bone Marrow Transplantation for Hematological Malignanciesâ€“Controversies and Recent Advances. Acta OncolÃ³gica, 1997, 36, 549-564.	0.8	42
265	Strong antileukemic effect of chronic graft-versus-host disease in allogeneic marrow transplant recipients having acute leukemia treated with methotrexate and cyclosporine. Transplantation Proceedings, 1997, 29, 733-734.	0.3	25
266	Transplantation with unrelated bone marrow in leukemic patients above 40 years of age. Transplantation Proceedings, 1997, 29, 3145-3146.	0.3	1
267	Donor search or autografting in patients with acute leukaemia who lack an HLA-identical sibling? A matched-pair analysis. Bone Marrow Transplantation, 1997, 19, 963-968.	1.3	45
268	Bone marrow transplantation using unrelated donors for haematological malignancies. Medical Oncology, 1997, 14, 11-22.	1.2	19
269	Generation of cytokines in red cell concentrates during storage is prevented by prestorage white cell reduction. Transfusion, 1997, 37, 678-684.	0.8	151
270	Serum levels of cytokines after bone marrow transplantation: increased ILâ€8 levels during severe venoâ€occlusive disease of the liver. European Journal of Haematology, 1997, 59, 254-262.	1.1	35

#	Article	IF	Citations
271	Prophylaxis and therapy using liposomal amphotericin B (AmBisome) for invasive fungal infections in children undergoing organ or allogeneic bone-marrow transplantation. Pediatric Transplantation, 1997, 1, 124-9.	0.5	22
272	Graft-versus-myeloma effect. Lancet, The, 1996, 348, 346.	6.3	78
273	A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. British Journal of Haematology, 1996, 93, 637-646.	1.2	133
274	The Highest Leukaemia-Free Survival After Allogeneic Bone Marrow Transplantation is Seen in Patients with Grade I Acute Graft-Versus-Host Disease. Leukemia and Lymphoma, 1996, 24, 71-79.	0.6	86
275	Transplantation of peripheral blood progenitor cells from unrelated donors. Bone Marrow Transplantation, 1996, 17 Suppl 2, S62-4.	1.3	1
276	Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplantation, 1996, 18, 921-9.	1.3	88
277	Long-term effects of hepatitis C virus infection in allogeneic bone marrow transplant recipients. Blood, 1995, 86, 1614-1618.	0.6	79
278	Lipid Formulations of Amphotericin B. Drug Safety, 1995, 13, 207-218.	1.4	59
279	Allogeneic bone marrow transplantation for lysosomal storage diseases. Lancet, The, 1995, 345, 1398-1402.	6.3	254
280	INCREASED LEVELS OF SOLUBLE INTERLEUKIN-2 RECEPTOR IN VENO-OCCLUSIVE DISEASE OF THE LIVER AFTER ALLOGENIC BONE MARROW TRANSPLANTATION. Transplantation, 1995, 60, 1293-1298.	0.5	22
281	Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplantation, 1995, 15, 619-25.	1.3	121
282	Ten years' experience of bone marrow transplantation for Gaucher disease. Transplantation, 1995, 59, 864-70.	0.5	36
283	Risk factors for septicemia during aplastic period after allogeneic bone marrow transplantation. Transplantation Proceedings, 1995, 27, 3530.	0.3	5
284	Transplantation with peripheral blood stem cells from unrelated donors without serious graft-versus-host disease. Bone Marrow Transplantation, 1995, 16, 856-7.	1.3	8
285	A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood, 1994, 83, 2723-2730.	0.6	330
286	Busulfan bioavailability. Blood, 1994, 84, 2144-2150.	0.6	183
287	Infection of donor lymphocytes with human T lymphotrophic virus type 1 (HTLVâ€Ⅰ) following allogeneic bone marrow transplantation for HTLVâ€Ⅰ positive adult Tâ€cell leukaemia. British Journal of Haematology, 1994, 88, 403-405.	1.2	49
288	Craniomandibular dysfunction in children treated with total-body irradiation and bone marrow transplantation. Acta Odontologica Scandinavica, 1994, 52, 99-105.	0.9	30

#	Article	IF	Citations
289	Identical-Twin Bone Marrow Transplants for Leukemia. Annals of Internal Medicine, 1994, 120, 646.	2.0	252
290	LONG-TERM FOLLOW-UP OF A RANDOMIZED TRIAL COMPARING T CELL DEPLETION WITH A COMBINATION OF METHOTREXATE AND CYCLOSPORINE IN ADULT LEUKEMIC MARROW TRANSPLANT RECIPIENTS. Transplantation, 1994, 58, 887-891.	0.5	27
291	Establishment of a tissue bank for fetal stem cell transplantation. Acta Obstetricia Et Gynecologica Scandinavica, 1994, 73, 385-388.	1.3	35
292	A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood, 1994, 83, 2723-2730.	0.6	5
293	Busulfan bioavailability. Blood, 1994, 84, 2144-2150.	0.6	3
294	Safety of liposomal amphotericin B (AmBisome) in 187 transplant recipients treated with cyclosporin. Bone Marrow Transplantation, 1994, 14 Suppl 5, S10-4.	1.3	13
295	A randomized trial comparing busulfan vs total body irradiation in allogeneic marrow transplant recipients with hematological malignancies. Transplantation Proceedings, 1994, 26, 1831-2.	0.3	8
296	High cure rate of invasive fungal infections in immunocompromised children using ambisome. Transplantation Proceedings, 1994, 26, 175-7.	0.3	10
297	A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood, 1994, 83, 2723-30.	0.6	95
298	Cytomegalovirus viraemia and specific T-helper cell responses as predictors of disease after allogeneic marrow transplantation. British Journal of Haematology, 1993, 83, 118-124.	1.2	79
299	Outcome After Allogeneic Bone Marrow Transplant for Leukemia in Older Adults. JAMA - Journal of the American Medical Association, 1993, 270, 57.	3.8	127
300	Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia?. Blood, 1993, 81, 1094-1101.	0.6	167
301	Liposomal amphotericin B (AmBisomeÂ®) treatment of invasive fungal infections in immunocompromised children. Mycoses, 1993, 36, 187-192.	1.8	23
302	Increased risk of relapse in patients with chronic myelogenous leukemia given Tâ€cell depleted marrow compared to methotrexate combined with cyclosporin or monotherapy for the prevention of graftâ€versusâ€host disease. European Journal of Haematology, 1993, 50, 269-274.	1.1	23
303	Management of graftâ€versusâ€host disease. European Journal of Haematology, 1993, 51, 1-12.	1.1	25
304	Outcome after allogeneic bone marrow transplant for leukemia in older adults. JAMA - Journal of the American Medical Association, 1993, 270, 57-60.	3.8	112
305	Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia?. Blood, 1993, 81, 1094-1101.	0.6	4
306	Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia?. Blood, 1993, 81, 1094-101.	0.6	44

#	Article	IF	Citations
307	Decreased transplant-related complications and improved leukemia-free survival in adults receiving methotrexate combined with cyclosporin compared with either agent alone for prevention of graft-versus-host disease. Advisory Committee of the International Bone Marrow Transplant Registry. Transplantation Proceedings, 1993, 25, 1241-2.	0.3	3
308	Foscarnet for Treatment of Cytomegalovirus Infections in Bone Marrow Transplant Recipients. Scandinavian Journal of Infectious Diseases, 1992, 24, 143-150.	1.5	49
309	Should HLA-identical sibling bone marrow transplants for leukemia be restricted to large centers? [see comments]. Blood, 1992, 79, 2771-2774.	0.6	50
310	Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. Blood, 1992, 80, 1090-1093.	0.6	177
311	Alterations in taste acuity associated with allogeneic bone marrow transplantation. Journal of Oral Pathology and Medicine, 1992, 21, 33-37.	1.4	61
312	Correlation of pretransplant viral serology and complications of bone marrow transplantation. Annals of Hematology, 1992, 64, A143-A147.	0.8	2
313	Should HLA-identical sibling bone marrow transplants for leukemia be restricted to large centers? [see comments]. Blood, 1992, 79, 2771-2774.	0.6	43
314	Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. Blood, 1992, 80, 1090-1093.	0.6	112
315	Allogeneic bone marrow transplantation: the Huddinge experience. Transplantation Proceedings, 1992, 24, 371-3.	0.3	1
316	Decreased incidence of graft-versus-host disease and improved survival with methotrexate combined with cyclosporin compared with monotherapy in recipients of bone marrow from donors other than HLA identical siblings. Bone Marrow Transplantation, 1992, 9, 19-25.	1.3	35
317	Craniofacial growth in bone marrow transplant recipients treated with growth hormone after total body irradiation. European Journal of Oral Sciences, 1991, 99, 44-47.	0.7	3
318	Isoamylase levels in bone marrow transplant patients are affected by total body irradiation and not by graft-versus-host disease. Transplant International, 1991, 4, 96-98.	0.8	4
319	Serum levels of alpha-1 microglobulin and beta-2 microglobulin in bone marrow transplant recipients treated with cyclosporin A. Transplant International, 1991, 4, 146-150.	0.8	6
320	Variables predicting oral mucosal lesions in allogenic bone marrow recipients. Head and Neck, 1991, 13, 224-229.	0.9	20
321	Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. Journal of Antimicrobial Chemotherapy, 1991, 28, 73-82.	1.3	285
322	Simultaneously presenting aplastic anaemia and Hodgkin's disease successfully treated with allogeneic bone marrow transplantation. European Journal of Haematology, 1991, 46, 314-316.	1.1	7
323	Methotrexate combined with cyclosporin A decreases graft-versus-host disease, but increases leukemic relapse compared to monotherapy. Bone Marrow Transplantation, 1991, 7, 113-9.	1.3	42
324	Prevention of graft-versus-host disease with T cell depletion or cyclosporin and methotrexate. A randomized trial in adult leukemic marrow recipients. Bone Marrow Transplantation, 1991, 7, 221-6.	1.3	66

#	Article	IF	Citations
325	Clinical and Biochemical Outcome of Marrow Transplantation for Gaucher Disease of the Norrbottnian Type. Acta Paediatrica, International Journal of Paediatrics, 1990, 79, 680-685.	0.7	55
326	Graft-versus-leukemia reactions after bone marrow transplantation. Blood, 1990, 75, 555-562.	0.6	2,566
327	Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood, 1990, 75, 2459-2464.	0.6	326
328	Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood, 1990, 75, 2459-2464.	0.6	5
329	Graft-versus-leukemia reactions after bone marrow transplantation. Blood, 1990, 75, 555-562.	0.6	43
330	Allogeneic bone marrow transplantations at Huddinge Hospital and strategies to improve survival. Clinical Transplants, 1990, , 175-87.	0.2	1
331	A role of herpes virus serology for the development of acute graft-versus-host disease. Leukaemia Working Party of the European Group for Bone Marrow Transplantation. Bone Marrow Transplantation, 1990, 5, 321-6.	1.3	31
332	Graft-versus-leukemia reactions after bone marrow transplantation. Blood, 1990, 75, 555-62.	0.6	738
333	Bone marrow transplantation for metabolic disorders at Huddinge Hospital. Transplantation Proceedings, 1990, 22, 198-202.	0.3	16
334	Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood, 1990, 75, 2459-64.	0.6	88
335	Serum levels of alpha-1 microglobulin in recipients of renal allografts. Transplant International, 1989, 2, 23-26.	0.8	5
336	Immunodeficiency associated with bone marrow transplantation. Current Opinion in Immunology, 1989, 1, 497-501.	2.4	1
337	Allogeneic Bone Marrow Transplantation Versus Chemotherapy in Children with Acute Leukemia in Sweden. Pediatric Hematology and Oncology, 1989, 6, 137-144.	0.3	8
338	Oral mucous membrane lesions in children treated with bone marrow transplantation. European Journal of Oral Sciences, 1989, 97, 268-277.	0.7	7
339	Influenza B in Transplant Patients. Scandinavian Journal of Infectious Diseases, 1989, 21, 349-350.	1.5	71
340	Serum levels of alpha-1 microglobulin in recipients of renal allografts. Transplant International, 1989, 2, 23-26.	0.8	2
341	Pretransplant herpes virus serology and chronic graft-versus-host disease. Bone Marrow Transplantation, 1989, 4, 547-52.	1.3	16
342	Variables predicting deep fungal infections in bone marrow transplant recipients. Bone Marrow Transplantation, 1989, 4, 635-41.	1.3	71

#	Article	IF	Citations
343	Graft-versus-leukemia reactions in humans. The Advisory Committee of the International Bone Marrow Transplant Registry. Transplantation Proceedings, 1989, 21, 2989-92.	0.3	46
344	LONG-TERM FOLLOW-UP OF THE FIRST SUCCESSFUL BONE MARROW TRANSPLANTATION IN GAUCHER DISEASE. Transplantation, 1988, 46, 66-69.	0.5	96
345	PRETRANSPLANT HERPESVIRUS SEROLOGY AND ACUTE GRAFT-VERSUS-HOST DISEASE. Transplantation, 1988, 46, 548-552.	0.5	48
346	Allogeneic bone marrow transplantation for leukemia: factors of importance for long-term survival and relapse. Bone Marrow Transplantation, 1988, 3, 281-90.	1.3	23
347	Spontaneous antibody secretion and DNA synthesis in blood lymphocytes increase during acute graft-versus-host disease. Transplantation Proceedings, 1988, 20, 503-5.	0.3	0
348	Allogeneic bone marrow transplantation in children at Huddinge Hospital. Transplantation Proceedings, 1988, 20, 487-90.	0.3	0
349	VARIABLES PREDICTING BACTERIAL AND FUNGAL INFECTIONS AFTER ALLOGENEIC MARROW ENGRAFTMENT. Transplantation, 1987, 43, 393-398.	0.5	41
350	GRAFT-VERSUS-LEUKAEMIA ACTIVITY ASSOCIATED WITH CYTOMEGALOVIRUS ANTIBODY POSITIVE BONE MARROW DONORS IN ACUTE MYELOID LEUKAEMIA. Lancet, The, 1987, 329, 456-457.	6.3	12
351	Polyclonal Antibody Secretion during Acute Graft-versus-Host Disease. Scandinavian Journal of Immunology, 1987, 26, 469-476.	1.3	3
352	DNA synthesis in human blood mononuclear cells correlates with severity of acute graft-versus-host disease. Bone Marrow Transplantation, 1987, 2, 259-69.	1.3	3
353	Failure to prevent cytomegalovirus infection by cytomegalovirus hyperimmune plasma: a randomized trial by the Nordic Bone Marrow Transplantation Group. Bone Marrow Transplantation, 1987, 2, 299-305.	1.3	35
354	Hemorrhagic cystitis--a manifestation of graft versus host disease?. Bone Marrow Transplantation, 1987, 2, 19-25.	1.3	49
355	European experience of bone marrow transplantation for leukemia. Transplantation Proceedings, 1987, 19, 2600-4.	0.3	30
356	The Importance of Pre Bone Marrow Transplantation Serology in Determining Subsequent Cytomegalovirus Infection: An Analysis of Risk Factors. Scandinavian Journal of Infectious Diseases, 1986, 18, 199-209.	1.5	34
357	Reduced risk of recurrent leukaemia in bone marrow transplant recipients after cytomegalovirus infection. British Journal of Haematology, 1986, 63, 671-679.	1.2	68
358	Bone Marrow Transplantation in Three Patients with Multiple Myeloma. Acta Medica Scandinavica, 1986, 219, 523-527.	0.0	33
359	A randomized trial comparing use of cyclosporin and methotrexate for graft-versus-host disease prophylaxis in bone marrow transplant recipients with haematological malignancies. Bone Marrow Transplantation, 1986, 1, 41-51.	1.3	63
360	FASTER IMMUNOLOGICAL RECOVERY AFTER BONE MARROW TRANSPLANTATION IN PATIENTS WITHOUT CYTOMEGALOVIRUS INFECTION. Transplantation, 1985, 39, 377-384.	0.5	50

#	Article	IF	Citations
361	DEATH BY GRAFT-VERSUS-HOST DISEASE ASSOCIATED WITH HLA MISMATCH, HIGH RECIPIENT AGE, LOW MARROW CELL DOSE, AND SPLENECTOMY. Transplantation, 1985, 40, 39-44.	0.5	113
362	Intravenous Foscarnet for the Treatment of Severe Cytomegalovirus Infection in Allograft Recipients. Scandinavian Journal of Infectious Diseases, 1985, 17, 157-163.	1.5	111
363	An analysis of factors predisposing to chronic graft-versus-host disease. Experimental Hematology, 1985, 13, 1062-7.	0.2	64
364	Acyclovir prophylaxis in bone marrow transplant recipients. Scandinavian Journal of Infectious Diseases, Supplement, 1985, 47, 137-44.	0.3	32
365	Are Increased IgE-Levels a Signal of an Acute Graft-Versus-Host Reaction?. Immunological Reviews, 1983, 71, 57-76.	2.8	26
366	Markedly elevated serum IgE levels following allogeneic and syngeneic bone marrow transplantation. Blood, 1983, 61, 1190-1195.	0.6	54
367	Markedly elevated serum IgE levels following allogeneic and syngeneic bone marrow transplantation. Blood, 1983, 61, 1190-5.	0.6	7
368	THE FIRST INFANT TO SURVIVE A GENERALIZED BCG INFECTION. Acta Paediatrica, International Journal of Paediatrics, 1982, 71, 161-165.	0.7	5
369	Activation of Human T and B Cells by Rabbit Anti-Human beta2-Microglobulin. Scandinavian Journal of Immunology, 1980, 11, 121-130.	1.3	6
370	Successful Treatment with Prednisone of Graftâ€Versusâ€Host Disease in an Allogeneic Boneâ€Marrow Transplant Recipient. Scandinavian Journal of Haematology, 1979, 22, 333-338.	0.0	11
371	Use of Mitogens for the Functional Characterization of Human Lymphocyte Subpopulations. Scandinavian Journal of Immunology, 1976, 5, 125-134.	1.3	14
372	B-Cell Mitogenic Effects on Human Lymphocytes of Rabbit Anti-Human beta2-Microglobulin. Scandinavian Journal of Immunology, 1975, 4, 171-179.	1.3	60